<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37486495</PMID><DateCompleted><Year>2023</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0065-2598</ISSN><JournalIssue CitedMedium="Print"><Volume>1424</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Advances in experimental medicine and biology</Title><ISOAbbreviation>Adv Exp Med Biol</ISOAbbreviation></Journal><ArticleTitle>Signature-Based Computational Drug Repurposing for Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>201</StartPage><EndPage>211</EndPage><MedlinePgn>201-211</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/978-3-031-31982-2_22</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a late-onset fatal neurodegenerative disease characterized by progressive loss of the upper and lower motor neurons. There are currently limited approved drugs for the disorder, and for this reason the strategy of repositioning already approved therapeutics could exhibit a successful outcome. Herein, we used CMAP and L1000CDS<sup>2</sup> databases which include gene expression profiles datasets (genomic signatures) to identify potent compounds and classes of compounds which reverse disease's signature which could in turn reverse its phenotype. ALS signature was obtained by comparing gene expression of muscle biopsy specimens between diseased and healthy individuals. Statistical analysis was conducted to explore differentially transcripts in patients' samples. Then, the list of upregulated and downregulated genes was used to query both databases in order to determine molecules which downregulate the genes which are upregulated by ALS and vice versa. These compounds, based on their chemical structure along with known treatments, were clustered to reveal drugs with novel and potentially more effective mode of action with most of them predicted to affect pathways heavily involved in ALS. This evidence suggests that these compounds are strong candidates for moving to the next phase of the drug repurposing pipeline which is in vitro and in vivo experimental evaluation.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s), under exclusive license to Springer Nature Switzerland AG.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Papikinos</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Informatics, Bioinformatics and Human Electrophysiology Laboratory, Ionian University, Corfu, Greece. c20papi@ionio.gr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krokidis</LastName><ForeName>Marios G</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Informatics, Bioinformatics and Human Electrophysiology Laboratory, Ionian University, Corfu, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vrahatis</LastName><ForeName>Aris</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Informatics, Bioinformatics and Human Electrophysiology Laboratory, Ionian University, Corfu, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vlamos</LastName><ForeName>Panagiotis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Informatics, Bioinformatics and Human Electrophysiology Laboratory, Ionian University, Corfu, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Exarchos</LastName><ForeName>Themis P</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>Department of Informatics, Bioinformatics and Human Electrophysiology Laboratory, Ionian University, Corfu, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Exp Med Biol</MedlineTA><NlmUniqueID>0121103</NlmUniqueID><ISSNLinking>0065-2598</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059467" MajorTopicYN="N">Transcriptome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Connectivity MAP</Keyword><Keyword MajorTopicYN="N">Drug repurposing</Keyword><Keyword MajorTopicYN="N">Gene expression profiling</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>24</Day><Hour>13</Hour><Minute>8</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>24</Day><Hour>11</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37486495</ArticleId><ArticleId IdType="doi">10.1007/978-3-031-31982-2_22</ArticleId></ArticleIdList><ReferenceList><Title>Bibliography</Title><Reference><Citation>Amyotrophic Lateral Sclerosis (ALS) Fact Sheet. (n.d.). Retrieved from National Institute of Neurological disorders and Stroke: https://www.ninds.nih.gov/amyotrophic-lateral-sclerosis-als-fact-sheet</Citation></Reference><Reference><Citation>Bakay, M., Wang, Z., Melcon, G., Schiltz, L., Xuan, J., Zhao, P., &#x2026; Mandler, R. (2006). Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain. Retrieved from PubMed: https://pubmed.ncbi.nlm.nih.gov/16478798/</Citation></Reference><Reference><Citation>Bartus, R. T., B&#xe9;tourn&#xe9;, A., Basile, A., Peterson, B. L., Glass, J., &amp; Boulis, N. M. (2016). &#x3b2;2-Adrenoceptor agonists as novel, safe and potentially effective therapies for Amyotrophic lateral sclerosis (ALS). Neurobiology of Disease, 85: 11-24.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2015.10.006</ArticleId><ArticleId IdType="pubmed">26459114</ArticleId></ArticleIdList></Reference><Reference><Citation>Charif, S. E., Vassallu, M. F., Salva&#xf1;al, L., &amp; Igaz, L. M. (2022). Protein synthesis modulation as a therapeutic approach for amyotrophic lateral sclerosis and frontotemporal dementia. Neural Regeneration Research, 17: 1423&#x2013;1430.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1673-5374.330593</ArticleId><ArticleId IdType="pubmed">34916412</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, B., Ma, L., Paik, H., Sirota, M., Wei, W., Chua, M.-S., &#x2026; Butte, A. J. (2017). Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targets. Nature Communications. 8 16022. Retrieved from Nature Communications: https://www.nature.com/articles/ncomms16022</Citation></Reference><Reference><Citation>Das, A., Smith, J. A., Gibson, C., Varma, A. K., Ray, S. K., &amp; Banik, N. L. (2011). Estrogen receptor agonists and estrogen attenuate TNF-&#x3b1;-induced apoptosis in VSC4.1 motoneurons. The Journal of endocrinology, 208 171-182.</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/JOE-10-0338</ArticleId><ArticleId IdType="pubmed">21068071</ArticleId></ArticleIdList></Reference><Reference><Citation>Dovrolis, N., Kolios, G., Spyrou, G., &amp; Maroulakou, I. (2017). Laying in silico pipelines for drug repositioning: a paradigm in ensemble analysis for neurodegenerative diseases. Drug Discovery Today, 22 805-813. Retrieved from PubMed: https://pubmed.ncbi.nlm.nih.gov/28363518/</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drudis.2017.03.009</ArticleId><ArticleId IdType="pubmed">28363518</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan, Q., Reid, S. P., Clark, N. R., Wang, Z., Fernandez, N. F., Rouillard, A. D., &#x2026; Maayan, A. (2016). L1000CDS2: LINCS L1000 characteristic direction signatures search engine. npj Systems Biology and Applications. 2: 16015</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npjsba.2016.15</ArticleId><ArticleId IdType="pubmed">28413689</ArticleId><ArticleId IdType="pmc">5389891</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA-Approved Drugs for Treating ALS. (2022). Retrieved from The ALS Association: https://www.als.org/navigating-als/living-with-als/fda-approved-drugs</Citation></Reference><Reference><Citation>Fiscon, G., Conte, F., Amadio, S., Volont&#xe9;, C., &amp; Paci, P. (2021). Drug repurposing: A network-based approach to amyotrophic lateral sclerosis. Neurotherapeutics, 18 1678-1691.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-021-01064-z</ArticleId><ArticleId IdType="pubmed">33987813</ArticleId><ArticleId IdType="pmc">8609089</ArticleId></ArticleIdList></Reference><Reference><Citation>Hinchcliffe, M., &amp; Smith, A. (2017). Riluzole: Real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degenerative Neurological and Neuromuscular Disease, 7 61-70.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S135748</ArticleId><ArticleId IdType="pubmed">30050378</ArticleId><ArticleId IdType="pmc">6053101</ArticleId></ArticleIdList></Reference><Reference><Citation>How Do I Interpret Connectivity Scores, and What Is a &#x201c;Good&#x201d; Score? (2018, 06 21). Retrieved from [clue.io]: https://clue.io/connectopedia/connectivity_scores</Citation></Reference><Reference><Citation>Jarada, T. N., Rokne, J. G., &amp; Alhajj, R. (2020). A review of computational drug repositioning: strategies, approaches, opportunities, challenges, and directions. Retrieved from Journal of Cheminformatics: https://jcheminf.biomedcentral.com/articles/10.1186/s13321-020-00450-7</Citation></Reference><Reference><Citation>Jiao, B., Wang, M., Feng, H., Bao, H., Zhang, F., Wu, H., &#x2026; Shen, L. (2021). Downregulation of TOP2 modulates neurodegeneration caused by GGGGCC expanded repeats. Human Molecular Genetics, 30 893-901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddab079</ArticleId><ArticleId IdType="pubmed">33749734</ArticleId></ArticleIdList></Reference><Reference><Citation>Jourdan, J.-P., Bureau, R., Rochais, C., &amp; Dallemagne, P. (2020). Drug repositioning: A brief overview. Retrieved from Wiley Online Library: https://onlinelibrary.wiley.com/doi/full/10.1111/jphp.13273</Citation></Reference><Reference><Citation>Kabuta, T., Kinugawa, A., Tsuchiya, Y., Kabuta, C., Setsuie, R., Tateno, M., &#x2026; Wada, K. (2009). Familial amyotrophic lateral sclerosis-linked mutant SOD1 aberrantly interacts with tubulin. Biochemical and Biophysical Research Communications, 387 121-126.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.06.138</ArticleId><ArticleId IdType="pubmed">19576169</ArticleId></ArticleIdList></Reference><Reference><Citation>Karatzas, E., Kolios, G., &amp; Spyrou, G. M. (2019). An application of computational drug repurposing based on transcriptomic signatures. Methods in Molecular Biology. Retrieved from PubMed: https://pubmed.ncbi.nlm.nih.gov/30547441/</Citation></Reference><Reference><Citation>Liu, J., &amp; Wang, F. (2017). Role of neuroinflammation in amyotrophic lateral sclerosis: Cellular mechanisms and therapeutic implications. Frontiers in Immunology. 8 1005</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01005</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId><ArticleId IdType="pmc">5567007</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, R., Wei, L., &amp; Zhang, P. (2021). A deep learning framework for drug repurposing via emulating clinical trials on real-world patient data. Nature Machine Intelligence. 3 65</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42256-020-00276-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo, Y.-C., Rensi, S.E., Torng, W, &amp; Altman, R.B. (2018, 08). Machine learning in chemoinformatics and drug discovery. Retrieved from Science Direct: https://www.sciencedirect.com/science/article/pii/S1359644617304695</Citation></Reference><Reference><Citation>Paik, H., Chung, A.-Y., Park, H.-C., Park, R. W., Suk, K., Kim, J., &#x2026; Butte, A. J. (2015). Repurpose terbutaline sulfate for amyotrophic lateral sclerosis using electronic medical records. Scientific Reports. 5:8580</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep08580</ArticleId><ArticleId IdType="pubmed">25739475</ArticleId><ArticleId IdType="pmc">4894399</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomo, V., Nozal, V., Rojas-Prats, E., Gil, C., &amp; Martinez, A. (2020). Protein kinase inhibitors for amyotrophic lateral sclerosis therapy. British Journal of Pharmacology. 178 (6), 1316-1335</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15221</ArticleId><ArticleId IdType="pubmed">32737989</ArticleId></ArticleIdList></Reference><Reference><Citation>Pompl, P. N., Ho, L., Bianchi, M., McManus, T., Qin, W., &amp; Pasinetti, G. M. (2003). A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. The FASEB Journal, 17 725-727.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-0876fje</ArticleId><ArticleId IdType="pubmed">12586733</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., &amp; Smyth, G. K. (2020, 01). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. Retrieved from PubMed: https://pubmed.ncbi.nlm.nih.gov/25605792/</Citation></Reference><Reference><Citation>Rudrapal, M., Khairnar, S. J., &amp; Jadhav, A. G. (2020). Drug repurposing (DR): An emerging approach in drug discovery. IntechOpen. Retrieved from IntechOpen: https://www.intechopen.com/chapters/72744</Citation></Reference><Reference><Citation>Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., &#x2026; Wadde, D. (2017, 11 30). A next generation connectivity map: L1000 Platform and the First 1,000,000 Profiles. Cell. Retrieved from PubMed: https://pubmed.ncbi.nlm.nih.gov/29195078/</Citation></Reference><Reference><Citation>Wagner, A., Cohen, N., Kelder, T., Amit, U., Liebman, E., Steinberg, D. M., &#x2026; Ruppin, E. (2015). Drugs that reverse disease transcriptomic signatures are more effective in a mouse model of dyslipidemia. Molecular Systems Biology. Retrieved from National Library of Medicine: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380926/</Citation></Reference><Reference><Citation>Wang, Z., Lachmann, A., Keenan, A. B., &amp; Ma&#x2019;ayan, A. (2018). L1000FWD: fireworks visualization of drug-induced transcriptomic signatures. Bioinformatics. 34: 2150-2152</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bioinformatics/bty060</ArticleId><ArticleId IdType="pubmed">29420694</ArticleId><ArticleId IdType="pmc">6454499</ArticleId></ArticleIdList></Reference><Reference><Citation>Watanabe, K., Tanaka, M., Yuki, S., Hirai, M., &amp; Yamamoto, Y. (2018). How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? Journal of Clinical Biochemistry and Nutrition, 62; 20-38.</Citation><ArticleIdList><ArticleId IdType="doi">10.3164/jcbn.17-62</ArticleId><ArticleId IdType="pubmed">29371752</ArticleId></ArticleIdList></Reference><Reference><Citation>Who Gets ALS? (2019, 05). Retrieved from The ALS Association Rocky Mountain Chapter: http://webco.alsa.org/site/PageServer/?pagename=CO_1_WhoGets.html</Citation></Reference><Reference><Citation>Zhou, Y., Hou, Y., Shen, J., Huang, Y., Martin, W., &amp; Cheng, F. (2020). Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discovery. 6: 14</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-020-0153-3</ArticleId><ArticleId IdType="pubmed">32194980</ArticleId><ArticleId IdType="pmc">7073332</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, K., Wang, Y., Sarlus, H., Geng, K., Nutma, E., Sun, J., &#x2026; Harriscorrespondin, R. A. (2022). Myeloid cell-specific topoisomerase 1 inhibition using DNA origami mitigates neuroinflammation. EMBO Reports.23(7): e54499</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embr.202154499</ArticleId><ArticleId IdType="pubmed">35593064</ArticleId><ArticleId IdType="pmc">9253741</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>